SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 76,808 shares, an increase of 44.8% from the January 15th total of 53,042 shares. Based on an average daily trading volume, of 462,687 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company’s shares are sold short. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 462,687 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SOPH shares. BTIG Research increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Guggenheim boosted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Wall Street Zen raised SOPHiA GENETICS to a “hold” rating in a research note on Saturday, November 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.00.

SOPHiA GENETICS Stock Down 0.2%

Shares of NASDAQ SOPH traded down $0.01 during midday trading on Monday, reaching $4.74. The company’s stock had a trading volume of 138,354 shares, compared to its average volume of 234,712. The stock has a 50 day simple moving average of $4.94 and a 200-day simple moving average of $4.31. The company has a current ratio of 2.80, a quick ratio of 2.62 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $320.33 million, a price-to-earnings ratio of -10.30 and a beta of 1.11. SOPHiA GENETICS has a fifty-two week low of $2.58 and a fifty-two week high of $5.70.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds have recently modified their holdings of SOPH. Green Alpha Advisors LLC raised its holdings in SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after acquiring an additional 4,444 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the last quarter. Savvy Advisors Inc. bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $48,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $49,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.